Genoveva Dragan

Accounting Manager at ADC Therapeutics - Epalinges, Vaud, CH

Genoveva Dragan's Colleagues at ADC Therapeutics
Niall McConnell

Head, Business Information Systems

Contact Niall McConnell

Sabine Soldan

Director, EU Regulatory Affairs

Contact Sabine Soldan

Ranmali Wijayaratne

Quality Control and Stability Management

Contact Ranmali Wijayaratne

Esohe Idusogie

Head of Process Quality and CMC Analytical

Contact Esohe Idusogie

Taylor Roland

Senior Marketing Manager - Patient and Digital Marketing

Contact Taylor Roland

View All Genoveva Dragan's Colleagues
Genoveva Dragan's Contact Details
HQ
+41 21 653 02 00
Location
Belmont-sur-Lausanne,Vaud,Switzerland
Company
ADC Therapeutics
Genoveva Dragan's Company Details
ADC Therapeutics logo, ADC Therapeutics contact details

ADC Therapeutics

Epalinges, Vaud, CH • 325 Employees
BioTech/Drugs

ADC Therapeutics is a commercial-stage global pioneer in the field of antibody drug conjugates (ADCs). Our goal is to be a leading ADC company that transforms the lives of those impacted by cancer. To achieve this, we are focused on unlocking the potential value of our robust ADC portfolio across two pillars of growth: hematology and solid tumors. We are a pioneer in the ADC field with specialized end-to-end capabilities unique to ADCs including a validated technology platform, a growing next-generation research & development toolbox and a proven track record that includes an approved and marketed product. We aim to expand our portfolio and accelerate the development of our pipeline through targeted investments and in collaboration with strategic partners. In this way, we plan to pursue multiple targets in parallel, enabling us to prioritize and ensure disciplined capital allocation strategy while advancing the most promising candidates in both hematology and solid tumors. Our CD19-directed ADC ZYNLONTA® (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. Founded in 2011, ADC Therapeutics is based in Lausanne, Switzerland, with operations in London and New Jersey. Our highly skilled global team is committed to confronting cancer with the full potential of our science and transforming the treatment paradigm for patients with cancer. For more information, please visit https://www.adctherapeutics.com/.

Cancer Research Targeted Cancer Therapies Solid Tumors Molecular Oncology Biopharmaceuticals Healthcare Innovation Clinical Trials Biotechnology
Details about ADC Therapeutics
Frequently Asked Questions about Genoveva Dragan
Genoveva Dragan currently works for ADC Therapeutics.
Genoveva Dragan's role at ADC Therapeutics is Accounting Manager.
Genoveva Dragan's email address is ***@adctherapeutics.com. To view Genoveva Dragan's full email address, please signup to ConnectPlex.
Genoveva Dragan works in the BioTech/Drugs industry.
Genoveva Dragan's colleagues at ADC Therapeutics are Sylvain Escolan, Niall McConnell, Sabine Soldan, Holt Robinson, Ranmali Wijayaratne, Esohe Idusogie, Taylor Roland and others.
Genoveva Dragan's phone number is +41 21 653 02 00
See more information about Genoveva Dragan